People · Operator
Named in public records as an officer, director or promoter · active 2016–2024 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ocugen, Inc. | — | Biotechnology | Series B | $145.6M | $566.9M | 2016 |
| Hyalex Orthopaedics, Inc. | — | Other Health Care | Series B | $30.4M | $91.1M | 2024 |
| LifeSprout, Inc. | — | Biotechnology | Series B | $23.9M | $841.2M | 2020 |
| Entera Bio Ltd. | — | Biotechnology | Series A | $22.2M | $44.8M | 2019 |
Adam Gridley at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Adam Gridley on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Johnson | 1 | 25 |
| Garheng Kong | 1 | 16 |
| Wende Hutton | 1 | 16 |
| Michael Lewis | 1 | 12 |
| Kevin Rakin | 1 | 7 |
| Patrick O'Donnell | 1 | 6 |
| Ron Mayron | 1 | 6 |
| Renee Ryan | 1 | 6 |
| V. Kadir Kadhiresan | 1 | 5 |
| Faith Charles | 1 | 4 |
| Ming Fang | 1 | 4 |
| Brad Vale | 1 | 4 |
| William Harrington | 1 | 4 |
| Gerald Ostrov | 1 | 3 |
| Sean Ellis | 1 | 3 |
| Miranda Toledano | 1 | 3 |
| Kevin McArdle | 1 | 3 |
| Peter Greenleaf | 1 | 3 |
| Shankar Musunuri | 1 | 2 |
| John Zhang | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.